spacer
home > epc > spring 2018 > data diligence
PUBLICATIONS
European Pharmaceutical Contractor

Data Diligence

Following headlines covering the Facebook and Cambridge Analytica saga, awareness of not only privacy issues, but also the underlying value of data held by corporations and how they are processed has heightened. One area highlighted in this article is how data collected by pharmaceutical companies is underutilised to inform data-driven decisionmaking across the board.

Unlocking Marketing Data

Traditionally, supply chain design and management has focused solely on sourcing products as well as distribution. However, many pharma companiesí supply chains are based on outdated legacy models where high demand and margins were once the norm. With the emergence of generic products, expiring patents, over-the-counter products, and an increased focus on emerging markets to deliver competitiveness, pharma companies need to design and introduce new supply chain models that require new systems, processes, and metrics to be implemented. The definition of supply chain management has broadened over the years, and, in the data-centric world people live in today, supply chain decision makers have begun realising the importance of regulatory, market, and healthcare professional client data, in designing more competitive supply chain models.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Kieran Bourke at MAXX Design is focused on the development of marketing solutions for pharma companies and has previously worked closely with GSK across its consumer marketing portfolio, helping them to innovate around the rapid rise of mobile marketing. He was previously a spokesperson for the Institute of Practitioners in Advertising.
spacer
Kieran Bourke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

Case Study: Cmedís Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

Nordic Life Science Days 2018

10-12 September 2018, Stockholm Waterfront Conference Center, Sweden

The Nordic way of doing life science business NLSDays offers networking and knowledge for anyone interested in the Nordic life science, biotechnologies, pharmaceuticals, medical devices and e-health business. We offer plenty of opportunities to connect.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement